WELCOME TO The Biotechnology REPORT
Newsletter | Member Login | Signup
Home > Companies > VINH PHUC PHARMACEUTICAL JOINT - STOCK COMPANY
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Conference
MedTech
SYNTHEGO | August 03, 2022
Synthego, the genome engineering company, announced the launch of Engineered Cell Libraries, a novel offering that further enables access to CRISPR by providing arrayed CRISPR-edited cells for direct use in functional screening assays. The innovative solution leverages Synthego’s Eclipse™ Platform. This high-throughput cell engineering platform delivers cell-based models for disease research by providing highly predictable CRISPR-engineered cells at scale through the integration of e...
Industrial Impact
Element Biosciences, Inc. | March 01, 2022
Element Biosciences, Inc., developer of a new and disruptive DNA sequencing platform, announced a partnership with 10x Genomics, a life sciences leader focused on mastering biology to advance human health, that demonstrates the seamless integration of the Element AVITI™ System and 10x Genomics’ single cell technologies. 10x Genomics’ Chromium Single Cell and Visium Spatial platforms enable researchers to examine biology at true resolution, combining hardware, che...
Medical
PacBio | April 23, 2022
PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the release of a transformative capability to detect DNA methylation using the Sequel IIe and Sequel II Systems. This extends PacBio’s unique and highly capable HiFi sequencing technology to now include access to the epigenome, a second layer of genomic information often left unexplored due to fundamental limitations of common sequencing technologies. PacBio’s single-mole...
Cell and Gene Therapy, Industry Outlook
Businesswire | May 09, 2023
Life Biosciences a biotechnology company advancing innovative cellular rejuvenation technologies to reverse diseases of aging and injury and ultimately restore health for patients, and Forge Biologics (“Forge”), a genetic medicines manufacturing organization, today announced a manufacturing partnership to help advance Life Bio’s partial epigenetic reprogramming platform to address aging-related diseases, including its lead program targeting ophthalmic indications.
Cell and Gene Therapy
Video
Cell and Gene Therapy, Medical
Whitepaper
Industry Outlook
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE